Market revenue in 2023 | USD 12.0 million |
Market revenue in 2030 | USD 37.5 million |
Growth rate | 17.7% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 60% in 2023. Horizon Databook has segmented the Canada plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The key factors contributing to growth of the market are increasing demand for pDNA in various medical therapies. Furthermore, the wide application of the pDNA in various therapeutic areas & diseases, including chronic diseases such as cardiovascular diseases, cancer, & autoimmune disorders, would increase the demand for pDNA manufacturing market.
Moreover, in Canada, cell therapies are limited to hospital settings in some areas, however, it is unclear whether limited hospital budgets & efforts to manage gene therapy costs would affect private payers.
The high cost of therapies leads to the need for sponsors to plan & design the sustainability of these therapies for chronic diseases like migraine & muscular dystrophy in the pipeline, as the spending has increased dramatically over the past 10 years.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Canada plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account